Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

NBTXR3, a first-in-class radioenhancer for pancreatic ductal adenocarcinoma: Report of first patient experience

Clinical and Translational Radiation Oncology(2022)10.1016/j.ctro.2021.12.012Source: DataRank Database

NBTXR3, a first-in-class radioenhancer for pancreatic ductal adenocarcinoma: Report of first patient experience is a research paper published in Clinical and Translational Radiation Oncology (2022). On theSindex it has a DataRank of 0. It has been cited 68 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access68 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (9 grants)Impact (FWCI 4.58)OA: goldTopics (20)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (19)

Ethan B. Ludmir ORCID,Anirban Maitra ORCID,Bruce D. Minsky ORCID,Grace L. Smith ORCID,Prajnan Das ORCID

Live enrichment

PubMed:35097226 PMC:PMC8783106 OpenAlex:https://openalex.org/W4206370214

National Institutes of Health

Grant: 1U10CA180858-01

UT MD Anderson Cancer Center Network Lead Academic Participating Site (LAP)

National Institutes of Health

Grant: 2U19CA021239-35

Assessing and Understanding the Impact of Physcial and Biological Factors on

NCI NIH HHS

Grant: R01 CA227517

National Institutes of Health

Grant: 3P30CA016672-41S4

Cancer Center Support (CORE) Grant

GE Healthcare

Philips Oral Healthcare

University of Texas MD Anderson Cancer Center

Radiation Oncology Institute

National Cancer Institute

FWCI

4.58

Citation Percentile

1.0%

Citation Trend

2022

2023

2024

2025

2026

goldLicense: cc-by-nc-nd

journalhttp://www.ctro.science/article/S2405630821001117/pdf

publisherhttp://www.ctro.science/article/S2405630821001117/pdf

publisherhttps://api.elsevier.com/content/article/PII:S2405630821001117?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2405630821001117?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.ctro.2021.12.012

Fields of Study

Nanoplatforms for cancer theranosticsRadiation Therapy and DosimetryRadiopharmaceutical Chemistry and Applications03 medical and health sciences0302 clinical medicine

Keywords

MedicineRadiation therapyPancreatic cancerRadiologyGemcitabineAdenocarcinomaAdverse effectCancerBrachytherapyInternal medicineMedical physics. Medical radiology. Nuclear medicineR895-920Neoplasms. Tumors. Oncology. Including cancer and carcinogensCase ReportRC254-282

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

NBTXR3, a first-in-class radioenhancer for pancreatic ductal adenocarcinoma: Report of first patient experience

FAIR Checklist

Authors (19)

Funding (9 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)